Nano Dimension to Buy Infinite Epigenetics in $890 Million AI Health Deal
The 3D-printing firm pivots to AI-powered preventive diagnostics, valuing the target at a 20% premium to its cash base.
**Nano Dimension Ltd. (NNDM) agreed to acquire Infinite Epigenetics in a proposed business combination that would value the AI-powered preventive-health diagnostics company at $890 million**. The transaction marks a strategic pivot for Nano Dimension, shifting its focus from 3D printing to epigenetics-driven chronic-disease detection.
The deal structure reflects a 20% premium to Nano Dimension’s estimated net cash at closing, with existing shareholders expected to retain a meaningful minority stake in the combined entity. Under the non-binding term sheet signed June 15, the parties aim to finalize a definitive agreement by July 31, with closing targeted for year-end, subject to regulatory and shareholder approvals.
**Nano Dimension’s board framed the deal as a long-term value creation opportunity, transitioning the company into a larger addressable market in AI-driven diagnostics**. The combined entity would operate under the Infinite Epigenetics name and trade on the Nasdaq Capital Market under the ticker symbol "IEAI," leveraging Nano Dimension’s capital base and public listing to accelerate growth. "While Infinite represents a transition of Nano’s operations from 3D printing to AI-powered preventive health and diagnostics, the Board believes the next wave of healthcare AI will be built on proprietary biological data, not generic medical text," said Nano Dimension’s leadership.
**Infinite Epigenetics brings a revenue-generating platform built on one of the largest private epigenetic datasets, with more than 120,000 samples collected since 2020**. The company’s proprietary biological AI foundation model interprets DNA methylation signals to predict chronic diseases such as cardiovascular disease, chronic obstructive pulmonary disease (COPD), and metabolic dysfunction-associated steatotic liver disease (MASLD). Its CLIA-certified lab and commercial operations serve a network of over 7,500 healthcare providers, positioning the platform to scale across a $90 billion U.S. clinical diagnostics market.
The deal follows a rigorous six-month strategic review in which Nano Dimension evaluated approximately 20 potential counterparties before selecting Infinite Epigenetics as the most compelling path forward. The transaction echoes recent sector precedents, including Exact Sciences’ validation of molecular diagnostics at scale and Tempus AI’s (TEM) public debut, which demonstrated the value of proprietary clinical data in precision medicine. Like Tempus, Infinite Epigenetics was co-founded by Brad Keywell, who emphasized the platform’s focus on biological data as a differentiator: "We believe the most valuable healthcare AI platforms will be built on proprietary biological data, leveraging AI for novel discoveries and insights".
**Regulatory and shareholder approvals remain key conditions for closing, with the combined company expected to hold over $400 million in cash at completion**. Nano Dimension’s capital base is projected to provide Infinite Epigenetics with sufficient runway to advance its AI model and commercial reach without additional capital raises, while pre-combination shareholders would receive a contingent value right tied to proceeds from the disposition of Nano’s legacy assets. Leadership of the combined entity would include Matt Dawson, Infinite Epigenetics’ current CEO, alongside a board featuring Keywell and retired U.S. Navy Vice Admiral Raquel "Rocky" Bono.